From: Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China
Target therapy | Patient number (N) | Best responsea | Median (average) DR (months) |
---|---|---|---|
Apatinib alone | 44 (78.6%) | PR | 3.8 (5.4) |
Apatinib+everolimus | 7 (12.5%) | PR | 8.5 (7.3) |
Apatinib+GTb | 5 (8.9%) | PR | 8.5 (7.3) |